6-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

---

Form6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-43048

NERVGEN PHARMACORP.

(Exact name of Registrant as specified in its charter)

---

N/A(Translation of Registrant’s name)

---

112-970 Burrard Street, Unit 1290Vancouver, British Columbia, Canada V6Z 2R4Telephone: (778) 731-1711

(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ¨   Form 40-F x

---

EXPLANATORY NOTE

---

Voluntary Delisting from TSX Venture Exchange

On March 12, 2026, NervGen Pharma Corp. (the “Company”) announced it will voluntarily delist the common shares of the Company from the TSX Venture Exchange (the “TSXV”) effective as of the close of trading on March 16, 2026. The Company’s common shares will no longer be traded on the TSXV but will continue to trade on the Nasdaq Capital Market under the symbol “NGEN.” A copy of the press release announcing the delisting is included in the Company’s material change report filed hereto as Exhibit 99.1.

The information contained in the press release is summary information that is intended to be considered in the context of our Securities and Exchange Commission filings and other public announcements that we may make, by press release or otherwise, from time to time.  We undertake no duty or obligation to publicly update or revise such information, except as required by law.

INCORPORATION BY REFERENCE

This Report on Form 6-K, including Exhibit 99.1, is incorporated by reference into the registrant’s Registration Statement on Form F-10 (File No. 333-292197), to be a part thereof from the date on which this Report on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit
99.1	Material Change Report, dated March 13, 2026.

---

---

SIGNATURES

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NERVGEN PHARMA CORP.
Date: March 13, 2026	By:	/s/ Adam Rogers
		Name:	Adam Rogers
		Title:	Chief Executive Officer

Exhibit 99.1

Form 51-102F3

MATERIAL CHANGE REPORT

Item 1.	Name and Address of Reporting Issuer

NervGen Pharma Corp. (“NervGen” or the “Company”)

112-970 Burrard Street, Unit 1290

Vancouver, BC V6Z 2R4

Item 2.	Date of Material Changes

March 12, 2026

Item 3.	News Releases

A news release announcing the material change was disseminated on March 12, 2026 through GlobeNewswire’s distribution network and a copy filed on NervGen’s SEDAR+ profile at www.sedarplus.ca.

Item 4.	Summary of Material Changes

On March 12, 2026, the Company announced that it has elected to voluntarily delist its common shares from TSX Venture Exchange (“TSXV”), effective at the close of markets on March 16, 2026.

Item 5.	Full Description of Material Changes

On March 12, 2026, the Company announced that it has elected to voluntarily delist its common shares from TSXV, effective at the close of markets on March 16, 2026.

This strategic decision reflects NervGen’s continued maturity and aligns with the Company’s evolution as it enters late-stage development for NVG-291. Following a comprehensive evaluation, the Company determined that maintaining a dual listing on TSXV does not justify the associated costs and administrative requirements. The voluntary delisting is intended to eliminate duplicative exchange fees, reduce legal, accounting, and regulatory complexity, and enable greater management focus on clinical execution and long-term shareholder value creation.

All shareholders, including Canadian shareholders, will continue to maintain full trading access of their common shares on Nasdaq. No action is required by shareholders in connection with the voluntary delisting. Shareholders with account-specific questions are encouraged to contact their respective brokers.

The voluntary delisting from TSXV was approved by the Company's Board of Directors. In accordance with TSXV policies, shareholder approval is not required as the Company’s common shares are listed on an acceptable alternative market. NervGen will continue to be a reporting issuer under applicable securities laws in all provinces and territories of Canada.

In connection with the voluntary delisting from TSXV, the Company has terminated its previously announced at-the-market equity program (the “ATM Program”), launched on December 19, 2025. From January 1, 2026, through March 12, 2026, the Company issued 245 common shares under the ATM Program at a weighted average price of $6.20 per common share, for aggregate net proceeds of $1,489.

Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7.	Omitted Information

No information has been omitted on the basis that it is confidential information.

Item 8.	Executive Officer

William Adams, Chief Financial Officer

112-970 Burrard Street, Unit 1290

Vancouver, BC V6Z 2R4

Item 9.	Date of Report

March 13, 2026